Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (181-190 of 379) with videos related to

Pageof 38
Sort By:
Investigational New Drugs|December 21, 2007
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemiaMarkus Jensen, Andreas Engert, Florian Weissinger, et al.
American Journal of Hematology|December 11, 2012
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphomaMaike Sauer, Annette Plütschow, Ron D Jachimowicz, et al.
Hemasphere|January 17, 2020
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-CenterJesko Momotow, Helen Goergen, Karolin Behringer, et al.
Blood|August 2, 2018
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Lena Schröder, et al.
Leukemia|August 23, 2018
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)Sven Borchmann, Horst Müller, Heinz Haverkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study GroupKarolin Behringer, Kai Breuer, Thorsten Reineke, et al.
Journal of Biotechnology|July 3, 2007
Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome displayAchim Rothe, Anne Nathanielsz, Ralf J Hosse, et al.
Biological Chemistry|May 26, 2012
A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cellsVijaya Lakshmi Simhadri, Hinrich P Hansen, Venkateswara R Simhadri, et al.
The Cochrane Database of Systematic Reviews|July 13, 2018
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)Marius Goldkuhle, Maria Dimaki, Gerald Gartlehner, et al.
Leukemia & Lymphoma|March 29, 2011
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphomaPeter Borchmann, Raoul Herbrecht, Martin Wilhelm, et al.
Pageof 38

Showing results (181-190 of 379) with videos related to

Sort By:
Pageof 38
Investigational New Drugs|December 21, 2007
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemiaMarkus Jensen, Andreas Engert, Florian Weissinger, et al.
American Journal of Hematology|December 11, 2012
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphomaMaike Sauer, Annette Plütschow, Ron D Jachimowicz, et al.
Hemasphere|January 17, 2020
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-CenterJesko Momotow, Helen Goergen, Karolin Behringer, et al.
Blood|August 2, 2018
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Lena Schröder, et al.
Leukemia|August 23, 2018
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)Sven Borchmann, Horst Müller, Heinz Haverkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study GroupKarolin Behringer, Kai Breuer, Thorsten Reineke, et al.
Journal of Biotechnology|July 3, 2007
Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome displayAchim Rothe, Anne Nathanielsz, Ralf J Hosse, et al.
Biological Chemistry|May 26, 2012
A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cellsVijaya Lakshmi Simhadri, Hinrich P Hansen, Venkateswara R Simhadri, et al.
The Cochrane Database of Systematic Reviews|July 13, 2018
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)Marius Goldkuhle, Maria Dimaki, Gerald Gartlehner, et al.
Leukemia & Lymphoma|March 29, 2011
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphomaPeter Borchmann, Raoul Herbrecht, Martin Wilhelm, et al.
Pageof 38